

Prescribing Clinical Network

| | |
|---|--|
| Policy Statement | Phosphodiesterase-5 inhibitors for the treatment of lower urinary tract symptoms in men |
| Policy No: | PCN 294- 2017 |
| Date of Issue | December - 2017 |
| Review Date: | December - 2020 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i> |
| <p>Recommendations: The PCN does not recommend the use of phosphodiesterase-5 inhibitors for the treatment of lower urinary tract symptoms in men except as part of a randomised controlled trial and has assigned a traffic light status to each treatment option as follows.</p> <ul style="list-style-type: none"> • Sildenafil - BLACK • Tadalafil – BLACK • Avenafil - BLACK • Vardenafil – BLACK <p>Patients whose treatment with the treatments above were initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.</p> | |
| <p>Key Considerations:</p> <ul style="list-style-type: none"> • CG97: Lower urinary tract symptoms in men -: management https://www.nice.org.uk/guidance/cg97/resources/lower-urinary-tract-symptoms-in-men-management-pdf-975754394053 | |
| Date taken to Prescribing Clinical Network | 6 th December 2017 |
| Agreed by PCN members | 18th December 2017 |

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG